Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England

Helen L Reeves, John Reicher, Georgia Priona, Derek M Manas, Peter Littler

ABSTRACT

Objective Hepatocellular carcinoma (HCC) deaths are rising alarmingly. Many patients are unsuitable for available therapies. Poor response rates further hamper outcomes for those that are. Selective internal radiation therapy (SIRT) offers hope, although which patients benefit over standard approaches remains unclear.

Design/method As a quality/service improvement, we audited consecutive patients treated with SIRT (2015-2020) by the Newcastle upon Tyne Hospitals National Health Service Foundation Trust HCC multidisciplinary team. Indications, Barcelona clinic liver cancer (BCLC) stage, treatment response, subsequent therapies and survival at 30 September 2021 were assessed.

Results Fifty-one patients received SIRT. Thirty-day mortality was zero. Three months partial response, stable disease and progressive disease on imaging were 50%, 22% and 28%, respectively. Overall median survival was 21 months. There were four subgroups: (1) BCLC-B: HCC<7cm too large for transarterial chemoembolisation (TACE) alone (n=21); (2) BCLC-B: HCC progressed post TACE (n=7); (3) BCLC-C: HCC with any combination of large tumour burden, branch portal vein thrombosis, non-hepatitis C virus aetiology (n=16); (4) BCLC-C: sorafenib inappropriate (n=7). In group 1, 5/21 (23.8%) of patients were downstaged to resection, 33% received subsequent medical therapies and median survival was >40 months. In BCLC-B patients treated second line (group 2), median survival was 14.2 months. In BCLC-C, median survival was 20.2 months for group 3 and 4.2 months for group 4.

Conclusion SIRT outcomes for advanced HCC, often bridging patients with adverse predictive factors to subsequent surgery or medical.
therapies, were encouraging. A role after TACE or for BCLC-C patients requires further assessment.

INTRODUCTION

Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally. For early-stage cancers, curative treatments such as resection, liver transplantation and ablation are considered. For those with multifocal tumours and preserved liver function, transarterial chemoembolisation (TACE) has been the mainstay of treatment. Unfortunately, the majority of patients with HCC in England present with advanced stage disease. Advanced HCC includes patients with greater size and numbers of tumours, portal vein invasion, metastatic spread, as well patients with deteriorating liver function and performance status regardless of tumour burden. HCC typically complicates underlying chronic liver disease and it is often liver function or comorbid conditions that limit treatment options. The importance of combination staging is widely recognised, with the Barcelona clinic liver cancer (BCLC) guideline and modifications of it, commonly used to aid treatment selection. Over the last decade, medical treatments for advanced disease have been introduced—with multikinase inhibitors available in both first-line (sorafenib, lenvatinib) and second-line (regorafenib) settings. The combination of atezolizumab immunotherapy and the vascular endothelial growth factor inhibitor bevacizumab (atezo/bev) is now also approved first line. In practice though, not all patients respond to medical therapies and few are ‘downstaged’ to surgical intervention. Additional therapeutic options are needed.

Radioembolisation, or selective internal radiation therapy (SIRT), is an alternative arterial therapy—delivering the cytotoxic radioisotope Yttrium-90 to cancers, rather than the typical chemoembolic beads used in TACE. SIRT has shown promise—with the potential to treat larger tumours. For TACE, benefit is reduced in tumours greater than 7 cm. Early studies also suggested SIRT benefit for patients with branch portal vein thrombosis (PVT)—PVT being an independent poor prognostic factor and one which is a contraindication to treatment with chemoembolisation. There has not been a large randomised control trial (RCT) comparing the efficacy of SIRT with TACE, but two RCTs have compared the efficacy of SIRT to sorafenib. SARAH (sorafenib versus radioembolization in advanced HCC) was a French trial that included patients with varied underlying aetiologies of liver disease, with either Child-Pugh A or B liver function. Although SIRT was well tolerated, there were no differences in progression-free or overall survival between the sorafenib and SIRT treated groups. The SIRveNIB (selective internal radiation therapy versus sorafenib) trial was based in the Asia Pacific region. Similarly, there were fewer adverse events reported with SIRT, but no differences in survival. As these trials failed to meet their primary endpoints of showing survival superiority, there is no RCT evidence base on which to recommend treatment with SIRT. Personalised dosimetry, with the delivery of tumour doses above 100 Gy with resin or 205 Gy with glass microspheres to advanced tumours, may achieve greater responses and improved overall survival compared with standard generic SIRT dosing. However, SIRT is not currently recommended for the treatment of patients with BCLC-C stage HCC.

In parallel, physicians, surgeons and healthcare providers have recognised that there are some patients where SIRT can play an important role, despite the lack of RCT evidence. In large retrospective series, improved survival in responders has been reported, with the LEGACY (local radioembolization using glass microspheres for the assessment of tumor control with Y-90) study published in 2021. LEGACY was a multicentre retrospective single arm study, in which 162 consecutive patients with solitary HCC≤8 cm, median tumour size 2.6 cm, Child-Pugh A cirrhosis and Eastern Cooperative Oncology Group performance status 0–1, were treated with radioembolisation. Clinically meaningful outcomes were observed, with prolonged durations of response and subsequent transplantation and resection subsequently performed in 21% and 6.8%, respectively. Consequently, the option to consider radioembolisation for BCLC-0 to BCLC-B stage patients has been recognised within the BCLC guideline.

In 2020–2021, the role of SIRT was reviewed in England by the National Institute for Health and Care Excellence (NICE), acting as an advisor to the National Health Service (NHS). Recognising that SIRT may have advantages for some patients acknowledging that many UK patients (older, lacking cirrhosis, with metabolic syndrome associated comorbidities) were not well represented in the evidence base underpinning international guidelines, NICE supported SIRT within a multidisciplinary team (MDT) setting as an option for treating unresectable advanced HCC in patients with Child-Pugh grade A liver impairment when conventional transarterial therapies are inappropriate. This is in keeping with the wider realisation that while evidence-based guidelines are immensely helpful, patient-specific characteristics and a centres expertise are important considerations when implementing a more personalised approach, with a positive impact on patient outcomes. The decision by NICE has been welcomed by the healthcare providers, patients and their advocacy groups. However, the absence of ‘a guideline’ presents a challenge, especially in centres where SIRT has not been accessible and expertise is currently lacking.

Supported by the Newcastle upon Tyne NHS Foundation Trust (NUTH), led within our hepatopancreatobiliary (HPB) MDT, treatment with SIRT has been
available for 7 years. We have audited our MDT practice, presented here with the aim of aiding decision-making for ‘real-world’ patients in England.

**MATERIALS AND METHODS**

In NUTH, between January 2015 and June 2020, SIRT treatment was available on an individual-named patient basis. HPB MDT review prior to its use was essential, with patient outcomes subject to audit as part of a quality/service improvement project (NUTH 10826). Glass microspheres were provided by Boston Scientific UK (2015–2019) and BTG thereafter. Selected patients were those where standard first-line therapies were not ideal. All patients had advanced disease, with Child-Pugh Grade A liver function. The majority were unsuitable for resection without prior downstaging, or had features associated with poorer responses to first-line TACE—based on a combination of lesion size, distribution or presence of PVT. This included patients with single lesions >7 cm² and those with partial (segmental or lobar branch) PVT. As features associated with poorer responses to sorafenib, large size and non-HCV-associated HCC aetiology were also considered in elderly patients with non-cancer-associated comorbidities impacting their quality of life. A pre-SIRT procedure was performed 2 weeks prior to SIRT, comprising angiography, cone-beam CT and injection of 150MBq Tc-99 macroaggregated albumin at the intended microsphere injection position(s). Treatment was administered as an in-patient, with clinical nurse specialist support. Data were collected retrospectively from the electronic patient record and Picture Archiving and Communication System, including indications for SIRT, disease response rates calculated according to modified response evaluation criteria in solid tumours (mRECIST) and survival with a minimum of 1-year follow-up at 30 September 2021. Data analyses were performed using IBM SPSS Statistics 25 licensed to Newcastle University.

**RESULTS**

**Patient characteristics**

A total of 51 patients with HCC were treated, with characteristics summarised in table 1. The median age was 72 years (range 39–84). Just over 80% were men. Fatty liver disease (one-third attributed to alcohol excess; two-thirds to obesity and the metabolic syndrome) was the most common underlying aetiology. Overall, 8/51 (15.7%) had no recognised chronic liver disease, while a further 12 (23.5%) had chronic liver without established cirrhosis. The majority had a European Co-operative Oncology Group (ECOG) performance status of 0–1, with 8/51 graded as 2. Overall, 39 (76.5%) had unilobar disease with 30 (58.8%) having a single lesion. The size of the largest lesion ranged from 3.3 to 19.1 cm (median 8.5 cm). Twelve patients (23.1%) had branch portal vein involvement. None had main portal vein involvement. In two-thirds, SIRT was administered first line. The median total activity of Yttrium-90 delivered was 3.2GBq.

**Patient outcome**

The treatment was well tolerated and 30-day mortality was 0. Overall, 50/51 patients had evaluable disease on imaging at 3 months, with 36/50 (72%) achieving at least a partial response or stable disease (table 1). At the time of last follow-up, five (9.8%) patients had gone on to have liver resection and remained alive. Two developed recurrence—one at 47.5 and one at 63.3 months post SIRT. Both are undergoing further treatment. Three (5.9%) remain under active follow-up without progression (median 26.1 months). Of the total 51 patients, 43 (82.4%) have progressed. One received further SIRT, with 12/43 (34.9%) having received subsequent medical therapies. Overall, 27/51 (52.9%) received supportive care second line. The median survival of the entire cohort was 20.17 months.

**Subgroup analysis**

Patients characteristics and outcomes were analysed within the categories for which SIRT treatment was advised within the MDT. The categories are detailed in table 1, including group (1) BCLC-B with HCC>7 cm (n=21); group (2) BCLC-B with HCC progression post TACE (n=7); group (3) BCLC-C with HCC feature associated with lesser response to sorafenib (large tumour burden, PVT, n=16); group (4) BCLC-C with a reason to avoid sorafenib (n=7).

BCLC-B patients in group 1 receiving first-line SIRT did well. Two received selective TACE in addition, as part of their initial treatment, to smaller distinct HCC outwith the SIRT-targeted lobes(s). The majority had further treatment, including 25% downstaged to resection (median size 15 cm), 14.3% remaining under active monitoring with stable disease and 19% receiving medical therapies after progression. Twelve are alive with a median survival in excess of 40 months. A case downstaged to resection is summarised in figure 1.

BCLC-B patients in group 2 were those treated with SIRT having developed recurrence or progression post first-line TACE (median TACE treatments 2 (range 1–7)). Two were subsequently treated with medical therapy (sorafenib), with an overall median survival of 14.8 months.

BCLC-C patients in group 3 were those considered for either sorafenib or SIRT in our MDT, with the options discussed with the patients. Typically, these were patients with comorbidities, large volume unilobar disease or portal vein invasion. In the first-line setting, the median survival of these patients was 27.4 months, with a median survival of 10.7 months for those with PVT.

BCLC-C patients in group 4 were a small eclectic group with advanced HCC and extenuating circumstances, offered SIRT after MDT discussion. These included patients with significant immunosuppression,
Liver inflammatory disease with impaired mobility and those intolerant of sorafenib. Median survival in this group was 4.2 months.

**DISCUSSION**

Although there is uncertainty about outcomes guided by RCT, NICE guidance approves NHS funding for SIRT treatment in unresectable patients with HCC and Child-Pugh A liver function, who are not suitable for conventional TACE. The guidance advises that SIRT beyond these criteria may be considered subject to a local MDT decision and funding availability within individual NHS Trusts.

Here, we have reviewed current evidence and described the practice of our MDT over a 4.5-year period, when SIRT was available to selected patients on a named patient basis, subject to review after a clinical care quality audit. We now incorporate this experience into our MDT decision-making, while noting the limitations—being from a single centre without a comparable control group of patients synchronously receiving standard care.

**Table 1** Patient characteristics and outcomes, considering all patients and 4 subgroups as recognised by the HPB MDT

|                          | All patients | Group 1 BCLC-B too large for TACE alone | Group 2 BCLC-B progression post TACE | Group 3 BCLC-C sorafenib eligible | Group 4 BCLC-C sorafenib unsuitable |
|--------------------------|--------------|-----------------------------------------|-------------------------------------|-----------------------------------|-------------------------------------|
| Patient number           | 51           | 21                                      | 7                                  | 16                                | 7                                   |
| age—median (range)       | 72 (39–84)   | 72 (51–84)                              | 76 (62–81)                         | 68 (50–81)                        | 72 (39–84)                          |
| Sex M/F                  | 41/10        | 15/6                                    | 6/1                                | 16/0                              | 4/3                                 |
| Aetiology—no CLD         | 8            | 3                                       | 0                                  | 2                                 | 3                                   |
| ARLD                     | 9            | 3                                       | 3                                  | 3                                 | 0                                   |
| NAFLD                    | 19           | 10                                      | 2                                  | 5                                 | 2                                   |
| HCV                      | 9            | 3                                       | 0                                  | 5                                 | 1                                   |
| Other                    | 6            | 2                                       | 2                                  | 1                                 | 1                                   |
| Cirrhosis N/Y            | 20/31        | 11/10                                   | 1/6                                | 5/11                              | 3/4                                 |
| Child-Pugh A             | 51           | 21                                      | 7                                  | 16                                | 7                                   |
| ECOG PST 0/1/2           | 21/22/8      | 14/7/0                                  | 3/4/0                              | 4/8/4                             | 0/3/4                               |
| Tumour number 1>1        | 30/21        | 14/7                                    | 2/5                                | 10/6                              | 4/3                                 |
| Size—median, cm (range)  | 8.5          | 9.7                                     | 5.9                                | 8.8                               | 8.3                                 |
| Total activity—median GBq (range) | 3.2          | 3.93                                    | 2.32                               | 3.20                              | 2.8                                 |
| Branch PVT N/Y           | 39/12        | 21/0                                    | 7/0                                | 6/10                              | 5/2                                 |
| Unilobar Y/N             | 39/12        | 16/5                                    | 5/2                                | 13/3                              | 5/2                                 |
| Prior therapy Y/N        | 17/34        | 2/19                                    | 7/0                                | 5/11                              | 3/4                                 |
| Next therapies           |              |                                         |                                    |                                   |                                     |
| Resection                | 5            | 5                                       | 0                                  | 0                                 | 0                                   |
| Active monitoring        | 3            | 3                                       | 0                                  | 0                                 | 0                                   |
| Further SIRT             | 1            | 0                                       | 0                                  | 1                                 | 0                                   |
| Medical 1 L              | 8            | 1                                       | 2                                  | 5                                 | 0                                   |
| Medical 1+2 L            | 7            | 3                                       | 0                                  | 3                                 | 1                                   |
| Supportive care          | 27           | 9                                       | 5                                  | 7                                 | 6                                   |
| mRECIST PR/SD/PD (3 months) | 25/11/14   | 12/6/2                                  | 2/0/5                              | 7/5/4                             | 4/0/3                               |

**Median survival (months)**

|                          | All—median 20.17 | Ongoing | 14.8 | 20.2 | 4.2 |
| Resection n=5            | Ongoing          | All alive | –     | –     | –   |
| Non-resected             | 15.5             | 21.7     | –     | –     | –   |
| First-line SIRT          | 21.67            | Ongoing  | –     | 27.4  | 3.7 |
| Second-line SIRT         | 10.93            | 42.1     | 14.8  | 10.7  | 7.3 |
| Unilobar                 | 19.87            | Ongoing  | 11.4  | 27.4  | 4.2 |
| Bilobar                  | 10.93            | 20.2     | 14.8  | 8.8   | 3.2 |
| +PVT                     | 10.7             | –        | –     | 10.7  | 2.7 |

ARLD, alcohol related liver disease; BCLC, Barcelona clinic liver cancer; CLD, chronic liver disease; ECOG PST, European Co-operative Oncology Group Performance Status; F, female; GBq, gigabecquerel; HCV, hepatitis C virus; 1L, first line; 2L, second line; M, male; mRECIST, modified response evaluation criteria in solid tumours; N, no; NAFLD, non-alcoholic fatty liver disease; PVT, portal vein thrombus; SIRT, selective internal radiation therapy; TACE, transarterial chemoembolisation; Y, yes.
of care options for patients with advanced BCLC-C HCC, or with BCLC-B progressive HCC post TACE, have changed in the last 5 years—with the approval of additional medical therapies.

The first noteworthy consideration, is that the number of patients treated with SIRT over the 4.5-year period in our centre, was relatively small, accounting for 51 (6.8%) of ~750 new referrals to our MDT in the same period. This reflects the use of SIRT in preference to standard therapies, in relatively small numbers, where our MDT considered it the best personalised treatment. The approval of SIRT by NICE is broadly in line with this approach.

Within the treated patient groups, the data from our audit support that of the DOSISPHERE-01 study and the role of SIRT for BCLC-B patients with HCC>7 cm, especially for unilobar or single lesions. In this group of patients, further therapies were facilitated in over 50%, with downstaging to surgical resection in 25%. As our patients had intermediate to advanced stage HCC, downstaging to liver transplantation was not addressed. However, the LEGACY study supports the use of SIRT in patients with single lesions of any size<8 cm in this setting. Presently, there is insufficient evidence that for smaller lesions, SIRT is superior to TACE and NICE guidance points to the use of TACE first line where possible. SIRT selection over TACE would need justification in an MDT setting.

MDTs might focus on those less likely to achieve effective bridging responses with combinations of TACE and ablation (eg, multifocal disease; single lesion approaching 5 cm; those at risk of decompensation post bridging therapy). Ideally, a change in practice of this nature would be subject to national co-operation and audit, informing future practice.

The outcomes for our BCLC-B patients with progressive disease post TACE were encouraging, but atezo/bev medical therapy is now an option for these patients. SIRT should be reserved for those in whom atezo/bev is not advisable (eg, immune disease; uncontrolled portal hypertension), with decision-making balanced against availability and suitability for other medical therapies and clinical trials. The outcomes of trials assessing the role of SIRT in combination with immunotherapies (eg, DOORwaY90, NCT04736121; NASIR-HCC, NCT03380130; MEDI4736, NCT04522544) are awaited and may inform changes in future practice, with earlier use of SIRT.

The outcomes for BCLC-C group 3 patients with unilobar HCC, as well as those with portal vein invasion, were also encouraging. Again though, large tumour burden and portal vein invasion are not features associated with resistance to atezo/bev. For patients with a single large lesion, a SIRT discussion in an MDT setting is reasonable, recognising the benefits of a single well-tolerated treatment that does not preclude future medical therapies.

The outcome for the heterogenous BCLC-C group 4 patients was not as good. Having said that, these were patients with advanced stage, where supportive care was the only alternative. Their poorer outcome as a group was not unexpected, with some individuals deriving significant benefit. In line with NICE guidance, within an MDT setting and pending approval of funding, SIRT may be considered for these patients.

**Overview and recommendation**

We all recognise that we should offer evidence-based therapies wherever possible, as well as support ongoing RCTs to inform future guidelines. However, regional access to services and RCTs is not equitable in the UK. Furthermore, many patients with HCC (older, with comorbidities) are either unsuitable for RCT inclusion or prefer not to travel to take part in RCTs. Regional MDTs play to their strengths, developing personalised approaches to suit the patients served. Within our NUTH MDT, we have explored SIRT and we are now in a position to offer it. Our recommendations are summarised in figure 2, advising limited deviation from evidence-based practice, but supporting local MDTs discretion when discussing available personalised approaches with their patients. With careful patient selection, the cost implications for individual NHS Trusts and Integrated Care Systems should be acceptable, while still ensuring that the necessary skills and expertise for SIRT delivery are developed and
maintained. While adopting this tactic, it is essential that all MDTs keep abreast of the rapidly changing landscape of treatment opportunities for patients with advanced HCC, moving to incorporate these as the evidence base evolves.

Twitter Helen L Reeves @HUNTER

Acknowledgements We thank all the members of our extended HPB MDT, in particular Ralph Jackson (radiology department) and David McCulloch (department of nuclear medicine). We thank Boston Scientific UK and BTG for provision of Ytrrium-90 spheres for our patients.

Contributors HLR, DMM and PL planned and delivered the study. HLR registered the study as an audit and was responsible for its reporting. HLR, JR and GP revised the manuscript. All authors agreed to submission of the manuscript. HLR, PL, DMM, JR and GP interpreted the data. HLR wrote the first draft of the manuscript. No individual identifiable patient information is included. T

Patient consent for publication Not applicable.

Ethics approval This study involves human participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The summary of the audit dataset is included in the manuscript. No individual identifiable patient information is included. To protect their identities—given the small numbers of patients, receiving a specific treatment in a defined time frame in an identified NHS Trust, the actual dataset is not provided.

Figure 2 Summary of recommendation for selective internal radiation therapy (SIRT) use within an England multidisciplinary team (MDT) setting. In England, patients with hepatocellular carcinoma (HCC) are managed within the National Health Service (NHS), referred to specialist centre MDTs in tertiary referral centre hospital trusts. The MDTs stage the patient, with the Barcelona clinic for liver cancer (BCLC) algorithm commonly used as a guide-aiding treatment selection by the MDT. The preferred first-line therapies for patients within each stage are shown. SIRT has been approved by the National Institute for Health and Care Excellence (NICE), as an alternative to transarterial chemoembolisation (TACE) first line, typically used for BCLC-B patients, if an MDT considers SIRT a more suitable option (green box). For BCLC-B patients responding to or downstaged by SIRT, subsequent treatments for earlier stage disease may be considered (dotted line to left). For BCLC-B patients who progress post SIRT, medical therapies would be considered (dotted line to right). NICE advised that SIRT for patients with BCLC 0-A, or BCLC-C stage HCC (highlighted **) and shown in orange boxes) could be considered as an alternative to preferred first-line therapies within the setting of an expert MDT, but offered subject to funding approval. ECOG PST, European Co-operative Oncology Group Performance Status; EHD, extrahepatic disease.

Twitter Helen L Reeves @HUNTER

Acknowledgements We thank all the members of our extended HPB MDT, in particular Ralph Jackson (radiology department) and David McCulloch (department of nuclear medicine). We thank Boston Scientific UK and BTG for provision of Ytrrium-90 spheres for our patients.

Contributors HLR, DMM and PL planned and delivered the study. HLR registered the study as an audit and was responsible for its reporting. HLR, JR and GP revised the manuscript. All authors agreed to submission of the manuscript. HLR, PL, DMM, JR and GP interpreted the data. HLR wrote the first draft of the manuscript. No individual identifiable patient information is included. T

Patient consent for publication Not applicable.

Ethics approval This study involves human participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The summary of the audit dataset is included in the manuscript. No individual identifiable patient information is included. To protect their identities—given the small numbers of patients, receiving a specific treatment in a defined time frame in an identified NHS Trust, the actual dataset is not provided.

Figure 2 Summary of recommendation for selective internal radiation therapy (SIRT) use within an England multidisciplinary team (MDT) setting. In England, patients with hepatocellular carcinoma (HCC) are managed within the National Health Service (NHS), referred to specialist centre MDTs in tertiary referral centre hospital trusts. The MDTs stage the patient, with the Barcelona clinic for liver cancer (BCLC) algorithm commonly used as a guide-aiding treatment selection by the MDT. The preferred first-line therapies for patients within each stage are shown. SIRT has been approved by the National Institute for Health and Care Excellence (NICE), as an alternative to transarterial chemoembolisation (TACE) first line, typically used for BCLC-B patients, if an MDT considers SIRT a more suitable option (green box). For BCLC-B patients responding to or downstaged by SIRT, subsequent treatments for earlier stage disease may be considered (dotted line to left). For BCLC-B patients who progress post SIRT, medical therapies would be considered (dotted line to right). NICE advised that SIRT for patients with BCLC 0-A, or BCLC-C stage HCC (highlighted **) and shown in orange boxes) could be considered as an alternative to preferred first-line therapies within the setting of an expert MDT, but offered subject to funding approval. ECOG PST, European Co-operative Oncology Group Performance Status; EHD, extrahepatic disease.

Twitter Helen L Reeves @HUNTER

Acknowledgements We thank all the members of our extended HPB MDT, in particular Ralph Jackson (radiology department) and David McCulloch (department of nuclear medicine). We thank Boston Scientific UK and BTG for provision of Ytrrium-90 spheres for our patients.

Contributors HLR, DMM and PL planned and delivered the study. HLR registered the study as an audit and was responsible for its reporting. HLR, JR and GP revised the manuscript. All authors agreed to submission of the manuscript. HLR, PL, DMM, JR and GP interpreted the data. HLR wrote the first draft of the manuscript. No individual identifiable patient information is included. T

Patient consent for publication Not applicable.

Ethics approval This study involves human participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The summary of the audit dataset is included in the manuscript. No individual identifiable patient information is included. To protect their identities—given the small numbers of patients, receiving a specific treatment in a defined time frame in an identified NHS Trust, the actual dataset is not provided.
Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

ORCID iD
Helen L Reeves http://orcid.org/0000-0003-0359-9795

REFERENCES
1 Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49.
2 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182–236.
3 Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity, type 2 diabetes and a multidisciplinary team. J Hepatol 2014;60:110–7.
4 Burton A, Balachandrarukumar VK, Driver RJ, et al. Regional variations in hepatocellular carcinoma incidence, routes to diagnosis, treatment and survival in England. Br J Cancer 2022;126:804–14.
5 Bolondi L, Burroughs A, Dufour J-F, et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions. Semin Liver Dis 2012;32:348–59.
6 Reig M, Forner A, Rimola J. BCLC strategy for prognosis prediction and treatment recommendation Barcelona clinic liver cancer (BCLC) staging system. The 2022 update. J Hepatol 2021.
7 Kadalayil L, Benini R, Pallan L, et al. A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 2013;24:2565–70.
8 Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol 2017;18:1624–36.
9 Chow PKH, Gandhi M, Tan S-B, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol 2018;36:1913–21.
10 Allimant C, Kafrouni M, Delicque J, et al. Tumor targeting and three-dimensional voxel-based dosimetry to predict tumor response, toxicity, and survival after yttrium-90 resin microsphere radioembolization in hepatocellular carcinoma. J Vasc Interv Radiol 2018;29:1662–70.
11 Garin E, Tselikas L, Guieu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021;6:17–29.
12 Riaz A, Gabr A, Abouchaleh N, et al. Radioembolization for hepatocellular carcinoma: statistical confirmation of improved survival in responders by landmark analyses. Hepatology 2018;67:873–83.
13 Salem R, Johnson GE, Kim E, et al. Yttrium-90 radioembolization for the treatment of solitary, unresectable HCC: the legacy study. Hepatology 2021;74:2342–52.
14 National Institute for Health and Care Excellence (NICE). Selective internal radiation therapies for treating hepatocellular carcinoma - Technology appraisal guidance [TA688], 2021. Available: https://www.nice.org.uk/guidance/ta688.
15 Matsumoto MM, Mouli S, Saxena P, et al. Comparing real world, personalized, multidisciplinary tumor board recommendations with BCLC algorithm: 321-Patient analysis. Cardiovasc Intervent Radiol 2021;44:1070–80.
16 Bruix J, Cheng A-L, Mehta R, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies. J Hepatol 2017;67:999–1008.
17 Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:552–60.
18 Llovet JM, Lencioni R. mRECIST for HCC: performance and novel refinements. J Hepatol 2020;72:288–306.
19 Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894–905.